Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lidocaine + ketamine (Hospices Civils de Lyon)
- Development stage
- Unknown
- Lead developer
- Hospices Civils de Lyon
- Modality
- Small Molecules
- Administration
- Intradermal
01
Overview
This investigational combination therapy consists of the local anesthetic lidocaine and the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine. Developed by Hospices Civils de Lyon, it is specifically being evaluated for the treatment of neuropathic pain associated with Complex Regional Pain Syndrome Type 1 (CRPS1). The treatment utilizes mesotherapy, a delivery technique involving multiple superficial microinjections (intra-epidermal and intradermal), which aims to provide targeted local analgesia while minimizing systemic exposure and associated side effects. Lidocaine acts by blocking voltage-gated sodium channels to inhibit nerve conduction and provide local vasodilation, while ketamine modulates central sensitization and neuropathic pain pathways by antagonizing NMDA receptors. The therapy is currently being studied in a Phase 2/3 clinical trial to determine the optimal dose and efficacy of the mixture.
- Other names
- Ketamine/Lidocaine Mesotherapy
02
Targets
NaV (Voltage-gated sodium channels)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on lidocaine + ketamine (Hospices Civils de Lyon).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lidocaine + ketamine (Hospices Civils de Lyon).